—

JOHNSON & JOHNSON

Q4 2025 13F Holdings

  • Location
    new brunswick, NJ
  • Num holdings

    17

  • Value ($000)

    $554,626

  • Date Filed
    02/13/2026
  • Form type
    13F-HR
  • CIK
    0000200406
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
P
PTGX

Protagonist Therapeutics Inc.

COM
74366E102
$213.91M
39 %

2,449,183

N
NBTX

Nanobiotix S.A.

SPONSORED ADS
63009J107
$130.02M
23 %

5,623,816

R
RAPP

Rapport Therapeutics, Inc.

COM
75383L102
$54.14M
10 %

1,784,517

---

MeiraGTx Holdings plc

COM
G59665102
$52.8M
10 %

6,641,064

C
CVRX

CVRx, Inc.

COM
126638105
$28.58M
5 %

4,024,861

C
CTNM

Contineum Therapeutics Inc.

CL A
21217B100
$22.62M
4 %

1,979,173

L
LEGN

Legend Biotech Corporation

SPONSORED ADS
52490G102
$17.71M
3 %

814,586

X
XNCR

Xencor, Inc.

COM
98401F105
$11.45M
2 %

748,062

P
PRCT

Procept BioRobotics Corporation

COM
74276L105
$11.26M
2 %

357,939

F
FATE

Fate Therapeutics, Inc.

COM
31189P102
$3.32M
1 %

3,379,064

Rows Per Page
10
  • 5
  • 10
  • 20
  • 30
  • 50
  • 100
1 - 10 of 17